December 4, 2025Advances in HematologyOpen Access

Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Single-institution analysis shows poor survival after treatment discontinuation in CLL, highlighting unmet needs for effective therapies.

Median progression-free survival from BTKi initiation was 3.2 years among CLL patients, indicating significant treatment effectiveness.
Following BTKi discontinuation, 80.6% of patients received additional therapies, with BCL2i leading to an overall response in 77.8%.
Median follow-up from BCL2i therapy initiation was 2.6 years, revealing high rates of treatment discontinuation and mortality.
These findings underscore urgent needs for new treatment strategies for chronic lymphocytic leukemia patients.

Lin et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark